Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical Trials

BACKGROUND: For new antibiotics developed to treat antibiotic-resistant Gram-negative infections, the US Food and Drug Administration (FDA) regulatory pathway includes complicated urinary tract infection (cUTI) clinical trials in which the clinical isolates are susceptible to the active control. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Portsmouth, Simon, Bass, Almasa, Echols, Roger, Tillotson, Glenn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953653/
https://www.ncbi.nlm.nih.gov/pubmed/33738315
http://dx.doi.org/10.1093/ofid/ofab045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953653/
https://www.ncbi.nlm.nih.gov/pubmed/33738315
http://dx.doi.org/10.1093/ofid/ofab045

Ejemplares similares